We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




American Pharmaceutical Firm to Aid Israelis Developing Personalized Medicine Drugs

By LabMedica International staff writers
Posted on 13 Jun 2016
A major American pharmaceutical company has signed a multi-year agreement to collaborate with an Israeli drug development center in the discovery and development of drugs for personalized medicine.

The Weizmann Institute of Science (Rehovot, Israel) and its commercial arm, Yeda Research and Development Co., Ltd. More...
(Rehovot, Israel), have entered into a multi-year arrangement with the American pharmaceuticals conglomerate Pfizer Inc. (New York, NY, USA).

Under the terms of the agreement Pfizer will place a medicinal chemist at the Weizmann Institute to assist with advancing target selection and high-throughput screening, as well as leading development campaigns for programs within the framework of the newly established National Drug Discovery Institute in the Nancy and Stephen Grand Israel National Center for Personalized Medicine.

Pfizer and Yeda will jointly evaluate the potential for additional agreements to promote development of drugs to address unmet medical needs.

“We are very pleased to collaborate with Pfizer, and to work side-by-side with its scientists in our new national center, to build a world-class discovery and medicinal chemistry organization,” said Dr. Berta Strulovici, head of the Nancy and Stephen Grand Israel National Center for Personalized Medicine at the Weizmann Institute of Science. “We welcome Pfizer’s commitment to scientific discovery, and we are excited to host Pfizer scientists on campus and to broaden the potential impact of our joint efforts and common aim to discover new medicines that may benefit patients around the world.”

“This is an exciting partnership for Pfizer,” said Mikael Dolsten, president of Pfizer Global Research, “We have interacted with the Weizmann Institute for many years and have confidence in their scientific vision and expertise. We anticipate that this arrangement could potentially result in meaningful discoveries in the coming years. We look forward to working with many Israeli scientists and to seeing the outcomes of this effort.”

Related Links:
Weizmann Institute of Science
Yeda Research and Development Co.
Pfizer


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Drug Test Kit
DrugCheck 3000
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.